LONG MINI-FUTURE - AMGEN | Delayed Deutsche Boerse AG 05:30:09 02/07/2024 pm IST | ||
| 9.53 EUR | -0.10% |
|
| Current month | -2.25% | ||
| 1 month | +6.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 02/24/02 | 9.53 | -0.10% |
| 01/24/01 | 9.54 | -2.25% |
| 28/24/28 | 9.76 | +0.21% |
| 27/24/27 | 9.74 | -1.42% |
| 26/24/26 | 9.88 | -5.18% |
Delayed Quote Deutsche Boerse AG
Last update July 02, 2024 at 05:30 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV16XP |
| ISIN | DE000VV16XP3 |
| Date issued | 06/05/2022 |
| Strike | 208.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.39 € |
|---|---|
| Lowest since issue | 1.72 € |
| Spread | 0.02 € |
| Spread % | 0.21% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
311
USD
Average target price
316.4
USD
Spread / Average Target
+1.75%
- Stock Market
- Certificates
- Certificat
